Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in ocular therapies, announced participation in two virtual healthcare investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a pre-recorded presentation available from September 13 at 7:00 a.m. ET. Additionally, the Cantor Global Healthcare Conference 2021 will have a presentation starting September 28 at 4:40 p.m. ET. Both events will allow for virtual one-on-one meetings. Archived recordings will be accessible on the company's website for at least 30 days.

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021:

H.C. Wainwright 23^rd Annual Global Investment Conference
A pre-recorded presentation will be made available beginning Monday, September 13, 2021 at 7:00 a.m. ET.

Cantor Global Healthcare Conference 2021
A pre-recorded presentation will be made available beginning Tuesday, September 28, 2021 at 4:40 p.m. ET.

Management will also be available for virtual 1x1 meetings on the same day as each presentation.

To access the webcasts and subsequent archived recording of each presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com. An archived replay of the presentations will be available on the Company’s website for at least 30 days following each event.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

What are the upcoming investor conferences for Kala Pharmaceuticals in September 2021?

Kala Pharmaceuticals will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor Global Healthcare Conference on September 28, both featuring pre-recorded presentations.

When can I access the presentations from Kala Pharmaceuticals' conferences?

The presentations will be available starting September 13 at 7:00 a.m. ET and September 28 at 4:40 p.m. ET, respectively.

How long will the archived presentations from Kala Pharmaceuticals be available?

Archived recordings of both presentations will be accessible on Kala's website for at least 30 days after each event.

What is Kala Pharmaceuticals known for?

Kala Pharmaceuticals focuses on the discovery and commercialization of innovative therapies for eye diseases, including their products EYSUVIS and INVELTYS.